Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010.
Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010.
复制标题
DOI：
10.1016/j.jacc.2013.05.064
复制
发表时间：
2013-08-20
影响因子：
24
通讯作者：
McElligott, Sean
中科院分区：
文献类型：
--
作者：
Beltran-Sanchez, Hiram;Harhay, Michael O.;Harhay, Meera M.;McElligott, Sean
按性别和种族描述美国成年人代谢综合征（MetS）的患病率、其五种组分及其药物治疗随时间的变化。代谢综合征是心血管疾病、中风、肾脏疾病和2型糖尿病的一系列临床危险因素。根据1999-2010年国家健康和营养检查调查（NHANES）（2年调查波）估计成人（≥20岁）的患病率估计值。2009年联合科学声明中定义的生物阈值为：（1）腰围≥ 102 cm（男性），≥ 88 cm（女性）（2）空腹血糖≥100 mg/dl（3）血压≥130/85 mm Hg（4）甘油三酯≥150 mg/dl（5）高密度脂蛋白胆固醇（HDL-C）<40 mg/dl（男性）和<50 mg/dl（雌性）。处方药的使用估计为调脂药，抗高血压药，抗高血糖药物。从1999/2000年到2009/10年，年龄校正的MetS患病率（基于生物学阈值）从25.5%（95%CI：22.5-28.6）降至22.9%（20.3-25.5）。在此期间，高血压患病率下降（33.5%至24.3%），血压升高（32.3%至24.0%）。高血糖的患病率增加（12.9%至19.9%），腰围增加（45.4%至56.1%）。这些趋势因性别和种族/族裔群体而有很大差异。高血压、次优甘油三酯和HDL-C患病率的降低分别与抗高血压和调脂药物的增加相对应。腹部肥胖的患病率不断增加，特别是在女性中，突出了解决腹部肥胖作为医疗保健优先事项的紧迫性。MetS组分治疗的使用与其患病率的有利趋势一致。
To characterize the prevalence of metabolic syndrome (MetS), its five components and their pharmacological treatment in US adults by gender and race over time. MetS is a constellation of clinical risk factors for cardiovascular disease, stroke, kidney disease and type 2 diabetes mellitus. Prevalence estimates were estimated in adults (≥20 years) from the National Health and Nutrition Examination Survey (NHANES) from 1999–2010 (in 2-year survey waves). The biological thresholds, defined by the 2009 Joint Scientific Statement, were: (1) waist circumference ≥ 102 cm (males), and ≥ 88 cm (females) (2) fasting plasma glucose ≥100 mg/dl (3) blood pressure of ≥130/85 mm Hg (4) triglycerides ≥150 mg/dl (5) high-density lipoprotein-cholesterol (HDL-C) <40 mg/dl (males) and <50 mg/dl (females). Prescription drug use was estimated for lipid-modifying agents, anti-hypertensives, and anti-hyperglycemic medications. From 1999/2000 to 2009/10, the age-adjusted prevalence of MetS (based on biologic thresholds) decreased from 25.5% (95%CI: 22.5–28.6) to 22.9% (20.3–25.5). During this period, hypertriglyceridemia prevalence decreased (33.5% to 24.3%), as did elevated blood pressure (32.3% to 24.0%). The prevalence of hyperglycemia increased (12.9% to 19.9%), as did elevated waist circumference (45.4% to 56.1%). These trends varied considerably by gender and race/ethnicity groups. Decreases in elevated blood pressure, suboptimal triglycerides and HDL-C prevalence have corresponded with increases in anti-hypertensive and lipid-modifying drugs, respectively. The increasing prevalence of abdominal obesity, particularly among females, highlights the urgency of addressing abdominal obesity as a healthcare priority. The use of therapies for MetS components aligns with favorable trends in their prevalence.
登录
查看更多内容
影响因子：
16.2
作者：
Ford, ES
通讯作者：
Ford, ES
影响因子：
120.7
作者：
Carroll, Margaret D.;Kit, Brian K.;Mussolino, Michael E.
通讯作者：
Mussolino, Michael E.
影响因子：
37.8
作者：
Wilson, PWF;D'Agostino, RB;Meigs, JB
通讯作者：
Meigs, JB
影响因子：
37.8
作者：
Alberti, K. G. M. M.;Eckel, Robert H.;Smith, Sidney C., Jr.
通讯作者：
Smith, Sidney C., Jr.
影响因子：
37.8
作者：
Malik, S;Wong, ND;Williams, GR
通讯作者：
Williams, GR